Three charts highlight the dangerous divergence in prospects across advanced economies and many emerging markets and developing countries.
[1/] Divergences in vaccine access.
Congratulations to the @nytimes on the Public Service #Pulitzer Award!
The need for real-time, reliable data has never been more pressing and the pandemic has shown how critical independent quality #journalism is to better decision making and public trust.
The staff of The New York Times has won the Pulitzer Prize for Public Service for coverage of the pandemic. Here are the award-winning pieces. nyti.ms/3xfE1ct
How much vaccine will be produced this year?
The third article of the series created in partnership with @SimonEvenett highlights the critical importance of globally distributing the huge number of vaccines likely to be produced this year. #CovidVaccineairfinity.com/insights/how-m…
Our #COVID19 vaccine insight of the day is our view on total doses produced and the number of doses that have actually been exported across countries/regions.
The enormous return on investment reflects the immense scale of the damage caused by the pandemic, @rasbech told @thetimes. “Vaccine production costs billions. But you get benefits in the order of trillions, so it’s worth doing.” 7/7
Read the full story:
thetimes.co.uk/article/brita…
The vaccine market is being transformed by COVID-19. Airfinity data predicts vaccine sales of @Novavax and @moderna_tx overtakes 3 of the largest existing players. ft.com/content/657b123a-78ba…
The biggest surprise of the vaccine delays to me was that it caught so many by surprise. But @TimHarford explains well why even that shouldn't be a surprise.
Why does so much from vaccines to our home work get delayed? @TimHarford makes some astute observations on the "planning fallacy" here citing @rasbech . Valuable insights for anyone planning ahead during a pandemic. ft.com/content/e79f0a2a-1de6…
We cannot vaccinate the world until the end of 2022, raising the risk of further dangerous variants and endemic Covid-19, warns @rasbech of @airfinity
Endemic Covid raises the challenge of annually vaccinating the whole world.
Full interview at:
youtu.be/kVIDPjnsVak
Glad that @Airfinity is collaborating with the brilliant C-19 team at the @FinancialTimes. I think the many journalists working day and night to accurately inform the public in a sea of misinformation are among the unsung heroes of this pandemic and we are proud to support them.
How should countries and international bodies build an effective vaccine responses? Our data suggests a broad range of accelerated public investments in trials, manufacturing, supply chain security and multi-technology investments are critical. Important piece in @FT .
Thank you for sharing @Airfinity data @EricTopol . With flurry of vaccine deals this changes daily. Here are numbers as of today (13th Dec). Happy to share more details. public.flourish.studio/story…
Before the vaccine problems with Sanofi-GSK (wrong dose) and Astra Zeneca/Oxford (? dose) the US was already short in covering its population
nature.com/articles/d41586-0… /2